Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cogent Biosciences (COGT – Research Report) and Altimmune (ALT – Research Report).
Cogent Biosciences (COGT)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Cogent Biosciences, with a price target of $19.00. The company’s shares closed last Monday at $7.36.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Cogent Biosciences is a Strong Buy with an average price target of $15.13, which is a 103.4% upside from current levels. In a report issued on February 12, Needham also maintained a Buy rating on the stock with a $15.00 price target.
See the top stocks recommended by analysts >>
Altimmune (ALT)
In a report released today, Corinne Johnson from Goldman Sachs maintained a Hold rating on Altimmune. The company’s shares closed last Monday at $10.94.
According to TipRanks.com, Johnson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Altimmune with a $22.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on COGT:
- Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Cogent Biosciences price target raised to $18 from $15 at Needham
- Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
- Cogent Biosciences announces ‘positive’ Part 1b data from SUMMIT trial
- Cogent Biosciences Launches $225M Private Stock Sale
